FASTURTEC 7.5 MG
RASBURICASE : 7.5 MG · DIN 02271397 · SANOFI-AVENTIS CANADA INC
Health Canada status: CANCELLED PRE MARKET
What is FASTURTEC?
FASTURTEC 7.5 MG contains RASBURICASE : 7.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02271397, held by SANOFI-AVENTIS CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled pre market, status dated 16-Jan-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02271397 |
|---|---|
| Brand name | FASTURTEC |
| Generic / active ingredient | RASBURICASE : 7.5 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 7.5 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | V03AF07 RASBURICASE |
| AHFS class | 44:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 16-Jan-2023 |
What can be used instead?
Other Canadian products sharing ATC code V03AF07 RASBURICASE. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| FASTURTEC | 1.5 MG | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02248416 |
Who else supplies RASBURICASE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RASBURICASE appears in 9 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.